[HTML][HTML] Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective …
LM Paschke, K Klimke, A Altiner, D von Stillfried… - BMC medicine, 2020 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are not only increasingly being
used for the initial stroke prevention therapy but progressively also substitute vitamin K …
used for the initial stroke prevention therapy but progressively also substitute vitamin K …
[HTML][HTML] Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German …
L Warkentin, S Hueber, B Deiters, F Klohn… - Thrombosis Journal, 2022 - Springer
Background For stroke prevention in patients with atrial fibrillation (AF), direct oral
anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists …
anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists …
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
SH Hohnloser, E Basic, M Nabauer - Clinical Research in Cardiology, 2017 - Springer
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …
Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review …
W Xu, M Lv, S Wu, S Jiang, Z Zeng, Z Fang… - … Drugs and Therapy, 2023 - Springer
Purpose We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …
Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis
C Escobar, J Marti-Almor, AP Cabeza… - Revista Española de …, 2019 - Elsevier
Introduction and objectives To assess the effectiveness of direct oral anticoagulants vs
vitamin K antagonists in real-life patients with atrial fibrillation. Methods A systematic review …
vitamin K antagonists in real-life patients with atrial fibrillation. Methods A systematic review …
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta …
F Ma, W Xu, J Chen, J Zhang - European Journal of Clinical …, 2023 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are associated with bleeding.
Patients often stop taking DOACs due to non-major bleeding, which may lead to stroke …
Patients often stop taking DOACs due to non-major bleeding, which may lead to stroke …
[HTML][HTML] Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
O Königsbrügge, A Simon, H Domanovits… - BMC cardiovascular …, 2016 - Springer
Background The clinical practice of stroke prevention in atrial fibrillation (AF) with direct oral
anticoagulants (DOACS) differs from anticoagulation in randomized trial patients. We …
anticoagulants (DOACS) differs from anticoagulation in randomized trial patients. We …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille, T Stammschulte… - European journal of …, 2018 - Springer
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
[HTML][HTML] Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities
PP Dobesh, J Fanikos - Drugs, 2015 - Springer
The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …